| Novartis highlights extensive data on numerous compounds at ASCO in multiple ... - Reuters (press release) |
|
|
Reuters (press release) Final results of the international Phase IV study, REACT (RAD001 Expanded Access Clinical Trial in RCC), evaluating Afinitor® (everolimus) tablets for the treatment of advanced renal cell carcinoma following any available vascular endothelial growth |